Tax advantages and economic moats allow master limited partnerships to offer investors much more than just high yields, says Morningstar's Paul Larson.
Facing dwindling drug pipelines, plenty of big pharma firms may end up jumping into the bidding for Genzyme, according to Morningstar's Karen Andersen.
Even if a potential Sanofi/Genzyme deal foretells a wave of consolidation, investors shouldn't worry about big pharma credit quality, says Morningstar's Julie Stralow.
Gen-Probe's CFO Herm Rosenman says the firm has plenty of catalysts that should drive growth for the next several years.
Among Vikram Pandit's last jobs as Citigroup Inc.'s chief executive officer was to decide the fate of the bank's hedge-fund unit, which employs some of his oldest colleagues. He agreed to give them most of it for free.
Proposal would have hiked continuing-education requirements for registrants; no shortage of comments.
Victor Fetter will move from Austin to Charlotte, N.C., to head the independent broker-dealer's growing IT squad.
©2012 Morningstar Advisor. All right reserved.